PE20110939A1 - Agente preventivo/terapeutico contra el cancer - Google Patents

Agente preventivo/terapeutico contra el cancer

Info

Publication number
PE20110939A1
PE20110939A1 PE2011001293A PE2011001293A PE20110939A1 PE 20110939 A1 PE20110939 A1 PE 20110939A1 PE 2011001293 A PE2011001293 A PE 2011001293A PE 2011001293 A PE2011001293 A PE 2011001293A PE 20110939 A1 PE20110939 A1 PE 20110939A1
Authority
PE
Peru
Prior art keywords
alkyl
group
preventive
therapeutic agent
against cancer
Prior art date
Application number
PE2011001293A
Other languages
English (en)
Spanish (es)
Inventor
Hisanori Matsui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20110939A1 publication Critical patent/PE20110939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PE2011001293A 2008-12-29 2009-12-28 Agente preventivo/terapeutico contra el cancer PE20110939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29

Publications (1)

Publication Number Publication Date
PE20110939A1 true PE20110939A1 (es) 2012-01-19

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001293A PE20110939A1 (es) 2008-12-29 2009-12-28 Agente preventivo/terapeutico contra el cancer

Country Status (26)

Country Link
US (1) US20110312898A1 (enExample)
EP (1) EP2379053A1 (enExample)
JP (1) JP2012513982A (enExample)
KR (1) KR20110111420A (enExample)
CN (1) CN102333520B (enExample)
AR (1) AR074918A1 (enExample)
AU (1) AU2009334235A1 (enExample)
BR (1) BRPI0923663A2 (enExample)
CA (1) CA2748517A1 (enExample)
CL (1) CL2011001519A1 (enExample)
CO (1) CO6382105A2 (enExample)
CR (1) CR20110374A (enExample)
DO (1) DOP2011000163A (enExample)
EA (1) EA019738B1 (enExample)
EC (1) ECSP11011166A (enExample)
GE (1) GEP20146001B (enExample)
IL (1) IL212913A0 (enExample)
MA (1) MA32935B1 (enExample)
MX (1) MX2011006170A (enExample)
NZ (1) NZ593381A (enExample)
PE (1) PE20110939A1 (enExample)
TN (1) TN2011000250A1 (enExample)
TW (1) TW201029660A (enExample)
UY (1) UY32367A (enExample)
WO (1) WO2010076896A1 (enExample)
ZA (1) ZA201103627B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275433B1 (en) * 2008-04-30 2017-06-07 Kyoto University Metastin derivative and use thereof
MX2012006441A (es) * 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.
EP2585091B1 (en) * 2010-06-25 2014-09-10 Takeda Pharmaceutical Company Limited Sustained-release formulation comprising a metastin derivative
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
WO2016099232A2 (ru) * 2014-10-20 2016-06-23 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтический состав лечебно-профилактического действия и способ его приготовления
CA3038865A1 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating female infertility
WO2024206577A1 (en) * 2023-03-28 2024-10-03 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof
WO2025217074A1 (en) 2024-04-08 2025-10-16 Radionetics Oncology, Inc. Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063221A1 (ja) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited メタスチン誘導体およびその用途
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
WO2006001499A2 (en) * 2004-06-25 2006-01-05 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
CN1972959A (zh) * 2004-06-25 2007-05-30 武田药品工业株式会社 转移素衍生物及其用途
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos

Also Published As

Publication number Publication date
CN102333520A (zh) 2012-01-25
TN2011000250A1 (en) 2012-12-17
JP2012513982A (ja) 2012-06-21
AU2009334235A1 (en) 2010-07-08
UY32367A (es) 2010-07-30
EP2379053A1 (en) 2011-10-26
AR074918A1 (es) 2011-02-23
CO6382105A2 (es) 2012-02-15
BRPI0923663A2 (pt) 2016-01-19
NZ593381A (en) 2013-01-25
IL212913A0 (en) 2011-07-31
EA201100882A1 (ru) 2011-12-30
KR20110111420A (ko) 2011-10-11
CL2011001519A1 (es) 2012-03-16
ZA201103627B (en) 2012-09-26
WO2010076896A1 (en) 2010-07-08
CN102333520B (zh) 2013-11-06
MA32935B1 (fr) 2012-01-02
CR20110374A (es) 2011-09-19
MX2011006170A (es) 2011-06-27
US20110312898A1 (en) 2011-12-22
DOP2011000163A (es) 2011-07-31
TW201029660A (en) 2010-08-16
ECSP11011166A (es) 2011-07-29
CA2748517A1 (en) 2010-07-08
EA019738B1 (ru) 2014-05-30
GEP20146001B (en) 2014-01-10

Similar Documents

Publication Publication Date Title
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
CO6270184A2 (es) Compuestos aromaticos y sus derivados con actividad biolëgica potenciadas contra la perdida de flujo intestinal
US20110150819A1 (en) Inhibition of bacterial biofilms with imidazole derivatives
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
US7662856B2 (en) Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
PE20060297A1 (es) Nuevos derivados fluoroglicosidicos de pirazoles como inhibidores de sglt 1
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
PE20061130A1 (es) Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
BRPI0409921A (pt) derivados de éster e amida de ácido 2-cianopropanóico e métodos de seu uso
NO20064282L (no) Morfolinforbindelser
PE20060875A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20081169A1 (es) Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
AU2021269232B2 (en) Non-lysosomal glucosylceramidase inhibitors and uses thereof
AR004413A1 (es) Compuestos de tiol que poseen actividad inhibitoria de metalopeptidasa; proceso para preparar dichos derivados; composiciones farmaceuticas que loscontienen

Legal Events

Date Code Title Description
FC Refusal